Basic mechanisms of gabitril (tiagabine) and future potential developments

被引：73

作者：

Meldrum, BS ^{[1
]}

Chapman, AG ^{[1
]}

机构：

[1] Univ London Kings Coll, Inst Psychiat, Dept Clin Neurosci, London SE5 8AF, England

来源：

EPILEPSIA | 1999年 / 40卷

关键词：

epilepsy; tiagabine; antiepileptic; GABA; mode of action;

D O I：

10.1111/j.1528-1157.1999.tb02087.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Gabitril (tiagabine) is a potent selective inhibitor of the principal neuronal gamma-aminobutyric acid (GABA) transporter (GAT-1) in the cortex and hippocampus. By slowing the reuptake: of synaptically-released GABA, it prolongs inhibitory postsynaptic potentials. In animal models of epilepsy, tiagabine is particularly effective against kindled (limbic) seizures and against reflexly-induced generalized convulsive seizures. These data are predictive of its efficacy in complex partial seizures in humans. Possible clinical applications outside the field of epilepsy include bipolar disorder and pain.

引用

页码：S2 / S6

页数：5

共 65 条

[1] Tiagabine - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy [J].

Adkins, JC ;

Noble, S .

DRUGS, 1998, 55 (03) :437-460

[2] Reduction of GABA and glutamate transporter messenger RNAs in the severe-seizure genetically epilepsy-prone rat [J].

Akbar, MT ;

Rattray, M ;

Williams, RJ ;

Chong, NWS ;

Meldrum, BS .

NEUROSCIENCE, 1998, 85 (04) :1235-1251

[3] ORALLY ACTIVE AND POTENT INHIBITORS OF GAMMA-AMINOBUTYRIC ACID UPTAKE [J].

ALI, FE ;

BONDINELL, WE ;

DANDRIDGE, PA ;

FRAZEE, JS ;

GARVEY, E ;

GIRARD, GR ;

KAISER, C ;

KU, TW ;

LAFFERTY, JJ ;

MOONSAMMY, GI ;

OH, HJ ;

RUSH, JA ;

SETLER, PE ;

STRINGER, OD ;

VENSLAVSKY, JW ;

VOLPE, BW ;

YUNGER, LM ;

ZIRKLE, CL .

JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (05) :653-660

[4] THE SYNTHESIS OF NOVEL GABA UPTAKE INHIBITORS .1. ELUCIDATION OF THE STRUCTURE-ACTIVITY STUDIES LEADING TO THE CHOICE OF (R)-1-[4,4-BIS(3-METHYL-2-THIENYL)-3-BUTENYL]-3-PIPERIDINECARBOXYLIC ACID (TIAGABINE) AS AN ANTICONVULSANT DRUG CANDIDATE [J].

ANDERSEN, KE ;

BRAESTRUP, C ;

GRONWALD, FC ;

JORGENSEN, AS ;

NIELSEN, EB ;

SONNEWALD, U ;

SORENSEN, PO ;

SUZDAK, PD ;

KNUTSEN, LJS .

JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (12) :1716-1725

[5] THE SYNTHESIS OF NOVEL GABA UPTAKE INHIBITORS .2. SYNTHESIS OF 5-HYDROXYTIAGABINE, A HUMAN METABOLITE OF THE GABA REUPTAKE INHIBITOR TIAGABINE [J].

ANDERSEN, KE ;

BEGTRUP, M ;

CHORGHADE, MS ;

LEE, EC ;

LAU, J ;

LUNDT, BF ;

PETERSEN, H ;

SORENSEN, PO ;

THOGERSEN, H .

TETRAHEDRON, 1994, 50 (29) :8699-8710

[6]

AUGOOD SJ, 1995, J NEUROSCI, V15, P865

[7]

BONNANO G, 1997, BRIT J PHARMACOL, V120, P60

[8] Gaba transporter heterogeneity: Pharmacology and cellular localization [J].

Borden, LA .

NEUROCHEMISTRY INTERNATIONAL, 1996, 29 (04) :335-356

[9] TIAGABINE, SK-AND-F 89976-A, CI-966, AND NNC-711 ARE SELECTIVE FOR THE CLONED GABA TRANSPORTER GAT-1 [J].

BORDEN, LA ;

DHAR, TGM ;

SMITH, KE ;

WEINSHANK, RL ;

BRANCHEK, TA ;

GLUCHOWSKI, C .

EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 269 (02) :219-224

[10] GABA-B RECEPTOR PHARMACOLOGY [J].

BOWERY, NG .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1993, 33 :109-147

← 1 2 3 4 5 6 7 →